I am writing in response to the following article, published in the Marietta Daily Journal on April 30, 2020: “A coronavirus drug seems to work. What’s next?” The article was quite apt with its descriptions regarding the FDA’s emergency use authorization for medications that may prove to be useful for treating diseases of public health concern. It is important for the public to know this type of information, so I would like to thank you for highlighting it in the article. In addition, I enjoyed reading the questions and answers at the end of the article regarding remdesivir as an investigational drug for treating COVID-19.
One of the questions addresses the issue of cost, which is important especially with the ongoing concerns and discussions relating to prescription drug prices. I believe it would have also been helpful to include information regarding possible side effects in order to provide a complete picture, especially for readers who might have some type of chronic disease. The study by Gilead did not include testing against a placebo group, which means there will need to be further testing to determine the drug’s safety. Also, about 1 in 4 patients treated with remdesivir side effects such as acute kidney or liver failure. Other than this additional information, I believe the article was quite comprehensive in discussing remdesivir as a possible treatment for COVID-19.